Clinical trials in pulmonary hypertension

Annual Review of Medicine

Volumn 48, Issue , 1997, Pages 399-408

  Badesch, David B ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Primary; Prostacyclin; Pulmonary hypertension; Secondary; Vasodilator

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIGITALIS; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN; HYDRALAZINE; ILOPROST; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTACYCLIN; SEX HORMONE; THROMBOXANE; VASODILATOR AGENT;

AUTOIMMUNITY; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DISEASE CLASSIFICATION; FEMALE; HEART ARRHYTHMIA; HEART RIGHT VENTRICLE FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPOTENSION; HYPOXEMIA; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ABUSE; INTRAVENOUS DRUG ADMINISTRATION; LUNG TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; OXYGEN THERAPY; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; SEX DIFFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME;

HUMANS; HYPERTENSION, PULMONARY; MULTICENTER STUDIES; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031051693     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.48.1.399     Document Type: Review

References (53)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. 1991. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115:343-49
2. Rich S, Kieras K, Hart K, et al. 1986. Antinuclear antibodies in primary pulmonary hypertension. J. Am. Coll. Cardiol. 8:1307-11
3. Isern RA, Yaneva M, Weiner E, et al. 1992. Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku. Am. J. Med. 93:307-12
4. Badesch DB, Wynne KM, Bonvallet S, et al. 1993. Hypothyroidism and primary pulmonary hypertension: an autoimmune pathogenetic link? Ann. Intern. Med. 119: 44-46
5. Speich R, Jenni R, Opravil M, et al. 1991. PPH in HIV infection. Chest 100:1268-71
6. Welsh CH, Hassell KC, Badesch DB, et al. 1996. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest. In press
7. Christman BW, McPherson CD, Newman JH, et al. 1992. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327:70-75
8. Moncada S, Gryglewski RJ, Bunting S, Vane JR. 1976. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:633-65
9. Hyman AL, Kadowitz PJ. 1979. Pulmonary vasodilator activity of prostacyclin in the cat. Circ. Res. 45:404-9
10. Moncada S, Vane JR. 1979. Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N. Engl. J. Med. 300:1142-47
11. Giaid A, Yanagisawa M, Langleben D, et al. 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328:1732-39
12. Yanagisawa M, Kurihara H, Kimura S, et al. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-15
13. Dubin D, Pratt RE, Kooke JP, Dzau VJ. 1989. Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J. Vasc. Biol. Med. 1:150-54
14. Komuro I, Kurihara H, Sugiyama T, et al. 1988. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett. 238: 249-52 [Erratum. 244:509]
15. Hirata Y, Takagi Y, Fukuda Y, Marumo F. 1989. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 78:225-28
16. Giaid A, Saleh D. 1995. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333:214-21
17. Ignarro LJ. 1989. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ. Res. 65:1-21
18. Palmer RMJ, Ashton DS, Moncada S. 1988. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333: 664-66
19. Ungerer R, Tashkin D, Furst D, et al. 1983. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am. J. Med. 75:65-74
20. Salerni R, Rodnan GP, Leon DF, Shaver JA. 1977. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann. Intern. Med. 86:394-99
21. Young RH, Mark GJ. 1978. Pulmonary vascular changes in scleroderma. Am. J. Med. 64:998-1004
22. Sfikakis P, Kyriakidis M, Vergos C, et al. 1991. Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril. Am. J. Med. 90:541-46
23. Morgan JM, Griffiths M, du Bois RM, Evans TW. 1991. Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest 99:551-56
24. Naslund M, Pearson T, Ritter J. 1981. A documented episode of pulmonary vasoconstriction in systemic sclerosis. Johns Hopkins Med. J. 148:78-80
25. Rozkovec A, Bernstein R, Atherton R, Oakley C. 1983. Vascular reactivity and pulmonary hypertension in systemic sclerosis. Arthritis Rheum. 26:1038-40
26. Shuck J, Oetgen W, Tesor J. 1985. Pulmonary vascular response during Raynaud's phenomenon in progressive systemic sclerosis. Am. J. Med. 78:221-27
27. Vergnon JM, Barthelemy JC, Riffat J, et al. 1992. Raynaud's phenomenon of the lung. A reality both in primary and secondary Raynaud syndrome. Chest 101:1312-17
28. Weir EK. 1990. Acute vasodilator testing and pharmacological treatment of primary pulmonary hypertension. In The Pulmonary Circulation: Normal and Abnormal. Mechanisms, Management, and the National Registry, ed. AP Fishman. Philadelphia: Univ. Penn. Press
29. DeFeyter PJ, Kerkkamp HJ, de Jong JP. 1983. Sustained beneficial effect of nifedipine in primary pulmonary hypertension. Am. Heart J. 105:333-34
30. Leier CV, Bambach D, Nelson S, et al. 1983. Captopril in primary pulmonary hypertension. Circulation 67:155-61
31. Lunde P, Rasmussen K. 1984. Long-term beneficial effect of nifedipine in primary pulmonary hypertension. Am. Heart J. 108: 415-16
32. Olivari MT, Levine TB, Weir EK, Cohn JN. 1984. Hemodynamic effects of nifedepine at rest and during exercise in primary pulmonary hypertension. Chest 86:14-19
33. Rich S, Brundage BH. 1987. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 76:135-41
34. Rubin LJ, Nicod P, Hillis LD, Firth BG. 1983. Treatment of primary pulmonary hypertension with nifedipine. Ann. Intern. Med. 99:433-37
35. Rubin LJ, Peter RH. 1980. Oralhydralazine therapy for primary pulmonary hypertension. N. Engl. J. Med. 302:69-74
36. Saito D, Haraoka S, Yoshida H, et al. 1983. Primary pulmonary hypertension improved by long-term oral administration of nifedipine. Am. Heart J. 105:1041-42
37. Rich S, Kaufman E, Levy PS. 1992. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. 327:76-81
38. Groves BM, Badesch DB, Turkevich D, et al. 1996. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival. In The Role of Ion Flux, in Pulmonary Vascular Control, ed. K Weir. New York: Plenum
39. Pietra GG, Edwards WD, Kay JM, et al. 1989. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 80:1198-206
40. Fuster V, Steele PM, Edwards WD, et al. 1984. Primary pulmonary hypertension: natural history and importance of thrombosis. Circulation 70:580-87
41. Jamieson SW, Auger WR, Fidulo PF, et al. 1993. Experience and results with 150 pulmonary thromboendarterectomy operations over a 29 month period. J. Thorac. Cardiovasc. Surg. 106:116-27
42. Alpert MA, Pressly TA, Mukerji V, et al. 1992. Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 102:1407-12
43. Glickson H, Pollack A, Dresser-Feigin R, et al. 1990. Nifedipine and prazocin in the management of pulmonary hypertension in CREST syndrome. Chest 98:759-61
44. Ocken S, Reinitz E, Strom J. 1983. Nifedi pine treatment for pulmonary hypertension in a patient with systemic sclerosis. Arthritis Rheum. 26:794-96
45. Fudman E, Kelling D Jr. 1985. Transient effect of nifedepine on pulmonary hypertension of systemic sclerosis. J. Rheum. 12:1191-92
46. Alpert MA, Pressly TA, Mukerji V, et al. 1991. Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. Am. J. Cardiol. 68:1187-91
47. Rubin LJ, Mendoza J, Hood M, et al. 1990. Treatment of primary pulmonary hypertension with continous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann. Intern. Med. 112:485-91
48. Barst RJ, Rubin LJ, Long WA, et al. 1996. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N. Engl. J. Med. 334:296-301
49. Barst RJ, Rubin LJ, McGoon MD, et al. 1994. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. 121:409-15
50. Olschewski H, Walmrath D, Schermuly R, et al. 1996. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann. Intern. Med. 124:820-24
51. Mata JDL, Gomez-Sanchez MA, Aranzana M, Gomez-Reino JJ. 1994. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum. 37: 1528-33
52. Channick RN, Williams PJ, Newhart JW, et al. 1996. Chronic inhaled nitric oxide in the outpatient treatment of primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 153:A86 (Abstr.)
53. Jansseus SP. 1996. Gene therapy for pulmonary hypertention: the new frontiers. Presented at 1996 Int. Conf. Am. Thorac. Soc.